Imara is dedicated to advancing new therapies to improve the lives of people living with sickle cell disease and other hemoglobinopathies.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $63M
Founded date: 2016
Investors 5
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| - | Arix Biosc... | arixbiosci... |
| - | Bay City C... | baycitycap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.03.2019 | Series B | $63M | OrbiMed |
Mentions in press and media 23
| Date | Title | Description |
| 16.10.2022 | Cancer drug biotech Enliven shifts to reverse to move forward as a public company | Drugs from a class called tyrosine kinase inhibitors have become standard treatments for some cancers, but the improved survival of patients taking these medicines introduces a new problem. As patients live longer, many decide they no longe... |
| 05.04.2022 | PhIIb implosion punts Imara back to preclinical mode as biotech axes programs in sickle cell disease, beta-thalassemia | Imara Therapeutics is shutting down its lead program in sickle cell disease and beta-thalassemia — including a pair of Phase IIb studies — after the latest interim readouts delivered unequivocally negative results.... |
| 19.07.2021 | The 5 biggest insider stock buys of last week | Here are the five top insider stock buys from last week. Companies include: Enovix, Imara, Cricut, SentinelOne, and Dirtt Environmental Solutions Advertisement Insider is watching which corporate executives are making big bets on their own ... |
| 19.07.2021 | The 5 biggest insider stock buys of last week | Here are the five top insider stock buys from last week. Companies include: Enovix, Imara, Cricut, SentinelOne, and Dirtt Environmental Solutions Sign up here for our daily newsletter, 10 Things Before the Opening Bell. Insider is watching ... |
| 01.12.2020 | Slone Partners Places Kevin B. Johnson as Senior Vice President of Regulatory Affairs at Inozyme Pharma | “Dr. Johnson is an experienced industry leader with extensive knowledge of the current regulatory landscape, in the United States and around the world.” said Slone Partners CEO Leslie Loveless. SOUTH RIDING, Va. (PRWEB) December 01, 2020 Sl... |
| 08.05.2020 | Ex-AstraZeneca exec Kristen Buck hops aboard Icon as CMO; Immunocore taps Brian DiDonato as CFO | Kristen Buck → Prominent CRO player Icon is bolstering its leadership, with Kristen Buck taking the reins as CMO. For slightly more than a year and a half, Buck was the SVP & chief of clinical development at Optum, part ... |
| 24.04.2020 | Laura Shawver on why she came back after an $88M windfall; MorphoSys taps Amgen vet as CCO | Laura Shawver Laura Shawver didn’t quite understand cancer until she had it. By that point, in 2006, she had already been making oncology drugs for over 15 years, a dyed-in-the-wool researcher who had obtained a PhD in pharma... |
| 18.02.2020 | As sickle cell patients find new options, NEA-founded Imara pitches mid-stage alternative for $86M IPO | November 2019 proved to be a fruitful month for patients with blood disorders known as hemoglobinopathies. Within days, the FDA ushered two drugs for sickle cell disease and another for beta thalassemia to the market — liv... |
| 19.03.2019 | Term Sheet — Tuesday, March 19 | UNICORN ALERT There’s a new unicorn on the block. Glossier, the direct-to-consumer beauty brand, raised $100 million in Series D funding at a $1.2 billion valuation. Sequoia Capital led the round, and was joined by a star-studded list of in... |
| 18.03.2019 | Imara lands $63M crossover round to trial sickle cell drug | Imara has raised a $63 million crossover round to advance its sickle cell disease drug. The series B will enable Imara to wrap up a phase 2a trial of a phosphodiesterase-9 inhibitor it picked up from Lundbeck and push deeper into the clinic... |
Show more